Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOXIRI plus chemoradiotherapy for high-risk locally advanced rectal cancer
NL-OMON52634Phase 2Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in rectal cancer, sponsored by Catharina Ziekenhuis. Primary endpoint: Complete pathological response or sustained clinical complete response at 1 year. Started Nov 2021; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON52634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52634.